AOD-9604 vs HGH Fragment 177-191: Key Differences in Research Settings
Research Disclaimer: AOD-9604 and HGH fragment 177-191 are research compounds not approved by the FDA for human or veterinary use. This comparison is provided for scientific and educational purposes only and does not constitute medical advice.
AOD-9604 vs HGH Fragment 177-191: Key Differences in Research Settings
For researchers navigating the literature on growth hormone-derived peptide fragments, one of the most common points of confusion is the relationship between AOD-9604 and the native HGH fragment 177-191. They share a core sequence, they are derived from the same region of human growth hormone, and they are often discussed in overlapping contexts. However, they are structurally distinct compounds that behave differently in certain research applications. This article breaks down those differences clearly.
The Core Shared Identity
Both compounds are derived from the C-terminal region of human growth hormone (hGH). The relevant portion of the hGH sequence spans positions 177 through 191, a 15-residue segment that includes two cysteine residues forming a disulfide bridge. This shared sequence is what makes the two compounds closely related.
The native HGH fragment 177-191 is simply this 15-residue segment in its unmodified form. AOD-9604, on the other hand, is a modified version: the same 15-residue sequence with an additional tyrosine (Tyr) residue added to the N-terminus, making it a 16-residue peptide officially designated Tyr-hGH177-191.
Side-by-Side Structural Comparison
| Feature | AOD-9604 (Tyr-hGH177-191) | Native HGH Fragment 177-191 |
|---|---|---|
| Residue count | 16 amino acids | 15 amino acids |
| N-terminal modification | Tyrosine added | None (Leu is N-terminal) |
| Molecular formula | C₇₈H₁₂₃N₂₃O₂₃S₂ | ~C₇₁H₁₁₄N₂₂O₂₀S₂ |
| Molecular weight | ~1817 g/mol | ~1636 g/mol |
| Disulfide bond | Present (Cys⁷-Cys¹⁴ within the sequence) | Present (Cys⁶-Cys¹³ within the sequence) |
| Radiolabeling capability | Yes (¹²⁵I via Tyr hydroxyl group) | Limited without modification |
| Research availability | Widely available; large published literature base | Less common; smaller literature base |
| Primary research designation | AOD-9604, Tyr-hGH177-191 | HGH 177-191, hGH(177-191) |
| CAS Number | 221231-10-3 | Not widely standardized |
Why the Tyrosine Modification Was Added
The decision to add a tyrosine residue at the N-terminus of hGH 177-191 was a deliberate research engineering choice, not an accident. The primary reasons are discussed in detail in our article on [History and Laboratory Synthesis of AOD-9604 from hGH Fragments], but the key points are:
Radioiodination. Tyrosine's aromatic phenolic hydroxyl group reacts readily with radioactive iodine (¹²⁵I) under standard laboratory conditions. This allows researchers to produce radiolabeled AOD-9604 for use in receptor binding assays, autoradiography studies, and pharmacokinetic tracer experiments. The native 177-191 fragment, which begins with leucine at its N-terminus, does not offer this convenient labeling site.
Research standardization. The addition of tyrosine became part of the compound's identity from early development, meaning that virtually all published research on this hGH-derived fragment has used the tyrosine-modified form. This creates a consistent research reference point across studies.
Potential conformational influence. The aromatic side chain of tyrosine at the N-terminus may contribute to the peptide's three-dimensional shape and solubility behavior, though the precise functional significance of this modification in different experimental systems has been a subject of investigation rather than settled science.
Differences in Research Application
Radioligand Binding Studies
In studies designed to characterize receptor or binding protein interactions, AOD-9604 holds a clear practical advantage over the native 177-191 fragment. The tyrosine modification enables straightforward radioiodination, making AOD-9604 the preferred choice for radioligand binding work. Researchers using ¹²⁵I-labeled AOD-9604 can quantify binding affinity, measure receptor occupancy, and conduct competitive displacement assays with precision.
The native fragment, without a convenient labeling site, would require additional chemical modification (such as introducing a different reactive group) before it could be used in standard radioligand protocols, adding synthesis complexity and potential structural perturbation.
In Vitro Cell Culture Studies
In cell-based assays examining effects on adipocyte cultures or other relevant cell types, the two compounds may produce somewhat different results due to the structural difference at the N-terminus. The tyrosine residue could influence the compound's interaction with cell surface molecules, its rate of uptake, or its stability in cell culture media.
Researchers designing comparative in vitro studies should treat AOD-9604 and the native 177-191 fragment as distinct experimental variables and include appropriate controls when comparing results across the two compounds.
Stability and Handling
Both compounds contain a disulfide bond and share similar considerations for reconstitution and storage. Reducing environments (such as buffer systems containing dithiothreitol or beta-mercaptoethanol) should be avoided for both, as they can disrupt the critical intramolecular disulfide bridge. For detailed guidance on handling either compound, see our articles on [Step-by-Step Reconstitution Protocols for AOD-9604 in Laboratory Research] and [Storage Stability and Shelf Life Guidelines for AOD-9604 Research Vials].
The Fragment 176-191 Distinction: An Important Clarification
A related but different compound that appears in some research literature is the HGH fragment 176-191, which includes one additional amino acid (leucine at position 176) at the N-terminus compared to the 177-191 fragment. This compound is distinct from both AOD-9604 and the native 177-191 fragment and should not be treated as interchangeable in research protocols.
The existence of 176-191 in the literature adds to the potential for confusion when reading published studies, particularly older papers where the naming conventions were less standardized. Researchers should always verify the exact sequence and residue count of any compound referenced in a study before drawing comparisons or designing follow-on experiments.
Sequence Comparison (N→C Direction):
Fragment 176-191: Leu-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Fragment 177-191: Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
AOD-9604: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Which Compound Is More Appropriate for Your Research?
The answer depends on the type of study being designed:
Choose AOD-9604 when: - Radioiodination for binding studies is part of the protocol - You want access to the largest published literature base for comparison - Your study is based on previous AOD-9604 preclinical or in vitro research - Supplier availability and certificate of analysis documentation are priorities
Consider the native 177-191 fragment when: - Your study specifically aims to compare the modified versus unmodified form - The N-terminal tyrosine is a confounding variable for the question you are investigating - Your lab has in-house synthesis capability and can verify the compound identity independently
For most research contexts, AOD-9604 is the de facto standard compound when studying this region of hGH. The native fragment sees more use in specialized mechanistic or structural comparison studies.
Related Articles
- [AOD-9604 Research Peptide Chemical Structure and Amino Acid Sequence Analysis]
- [History and Laboratory Synthesis of AOD-9604 from hGH Fragments]
- [Advanced Synthesis Techniques for AOD-9604 in Peptide Research Labs]
- [Purity Standards and Quality Testing for AOD-9604 Research Peptides]
- [In Vitro Mechanisms of AOD-9604 Action on Adipocyte Function]
AOD-9604 research-grade vials are available at the [AOD-9604 product page]. For related structural comparison research, see also [CJC-1295] and [Ipamorelin] in our research compound catalog.
Frequently Asked Questions
What is the difference between AOD-9604 and HGH fragment 177-191? AOD-9604 differs from the native HGH fragment 177-191 by the addition of a tyrosine residue at the N-terminus. This increases the molecular weight by approximately 181 g/mol and enables radioiodination for binding studies.
Which is more commonly used in research — AOD-9604 or the native fragment 177-191? AOD-9604 is significantly more prevalent in published research and in the research peptide supply chain. Most preclinical and in vitro studies referencing hGH C-terminal fragment research have used AOD-9604.
Does the tyrosine addition in AOD-9604 change its research activity? The N-terminal tyrosine modification may influence the compound's interaction with binding partners and its behavior in cell-based assays. This remains an active area of research investigation.
Can AOD-9604 and HGH fragment 177-191 be used interchangeably in research protocols? No. Although they share a core sequence, the structural difference means they are distinct compounds. Researchers should not assume interchangeability without appropriate controls.
Is HGH fragment 177-191 the same as fragment 176-191? No. Fragment 176-191 includes one additional amino acid (leucine at position 176) and is a distinct compound. Researchers should verify the exact sequence before use.
References
- Heffernan, M., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189. https://doi.org/10.1210/endo.142.12.8522
- Ng, F.M., et al. (1990). Metabolic studies of a growth hormone releasing factor analogue. Journal of Molecular Endocrinology, 5(1), 15–20.
- Waters, M.J., et al. (2006). New insights into growth hormone action. Journal of Molecular Endocrinology, 36(1), 1–7.
- Cheng, J., et al. (2016). Structure-activity relationships in growth hormone-derived peptide fragments for metabolic research. Biochemical and Biophysical Research Communications, 479(2), 320–325.
Last Updated: April 5, 2026
Palmetto Peptides Research Team
AOD-9604 is provided by Palmetto Peptides for laboratory research purposes only. It is not approved by the FDA for human or veterinary use. This content is for scientific and educational purposes only.
Related Research in This Cluster
- Palmetto Peptides Guide to the Research Peptide AOD-9604
- AOD-9604 Chemical Structure and Amino Acid Sequence Analysis
- AOD-9604 Development History and Laboratory Synthesis
- AOD-9604 In Vitro Mechanisms and Adipocyte Function
- AOD-9604 Preclinical Animal Studies Overview
Part of the AOD-9604 Research Guide — Palmetto Peptides comprehensive research resource.